Ambulatory blood pressure monitoring is a useful prognosis tool to differentiate between true and white coat resistant hypertension, according to a study published online March 28 in Hypertension.
TUESDAY, March 29 (HealthDay News) -- Ambulatory blood pressure monitoring is a useful prognosis tool to differentiate between true and white coat resistant hypertension, according to a study published online March 28 in Hypertension.
Alejandro de la Sierra, M.D., from the University of Barcelona in Spain, and colleagues estimated the prevalence of resistant hypertension in a large cohort of treated hypertensive patients from the Spanish ambulatory blood pressure monitoring (ABPM) registry, who had information on office blood pressure measurements, and good quality ABPM. They identified 8,295 patients with resistant hypertension, defined as office blood pressure greater than or equal to 140 over 90 mm Hg, while being treated with three or more hypertensive drugs including one diuretic.
The investigators found that, after ABPM, 62.5 percent of patients were defined as true resistant hypertensives, and 37.5 percent were classified as having white coat resistance. Those with true resistant hypertension were younger, more often male, had a longer duration of hypertension, and a worse cardiovascular risk profile. The true resistant group included larger proportions of smokers, diabetics, and those with target organ damage, including left ventricular hypertrophy, decreased renal function, and microalbuminuria, and previous cardiovascular disease.
"It must be emphasized that ABPM continues to be needed and must be encouraged for a correct diagnosis and management of all hypertensive patients not controlled on three or more antihypertensive drugs," the authors write.
Several authors disclosed financial ties to Lacer Laboratories.
AbstractFull Text (subscription or payment may be required)
Related Content
Addressing Maternal Obesity While Fostering Healthy HabitsAHA: Flavonoid-Rich Cocoa May Reduce Cardiovascular Risk
Study shows a healthy prenatal diet could be upstream obesity prevention strategy
December 26th 2024"Our findings support the recommendation of a healthy diet based on the current guidelines (as measured by the HEI) during pregnancy, since it may reduce patterns of infant growth outside reference ranges."
Read More
S1E4: Dr. Kristina Adams-Waldorf: Pandemics, pathogens and perseverance
July 16th 2020This episode of Pap Talk by Contemporary OB/GYN features an interview with Dr. Kristina Adams-Waldorf, Professor in the Department of Obstetrics and Gynecology and Adjunct Professor in Global Health at the University of Washington (UW) School of Medicine in Seattle.
Listen
Early pregnancy cannabis use high in states with recreational legalization
November 11th 2024A population-based time-series analysis California before, during and after legalization show a rising trend in women using cannabis while pregnancy especially when the state has legalized the drug.
Read More
Similar delivery times between misoprostol dosages among obese patients reported
May 29th 2024A recent study found that obese patients undergoing induction of labor experienced similar delivery times regardless of whether they received 50 μg or 25 μg of vaginal misoprostol, though multiparous patients showed faster delivery with the higher dosage.
Read More